Market news, stock analysis and investing ideas

TransMedics Raises 2026 Revenue Outlook After 41% Q3 Growth; Adjusted EPS Dips

TransMedics' third-quarter revenue rose 41% to $203.0 million and the company raised its 2026 revenue forecast, but adjusted EPS of $0.51 trailed last year's $0.67. Shares closed Friday 27.92% above Thursday's close.

TransMedics Raises 2026 Revenue Outlook After 41% Q3 Growth; Adjusted EPS Dips

TransMedics Group, Inc. (NASDAQ: TMDX) reported third-quarter results at 4:02 p.m. ET on Nov. 5, 2026, in after-hours trading (the session after the 4:00 p.m. close). Revenue was $203.0 million, up 41% from a year earlier, and the company raised its 2026 revenue guidance (its own forecast) to $764 million to $774 million, including about $14 million from PAD Aviation. The company also filed the results in an 8-K.

Revenue and guidance rose, per-share profit fell

Adjusted earnings per share (a non-GAAP measure that leaves out some items) were $0.51, against $0.67 a year earlier. Operating expenses rose to $90.5 million from $61.3 million, and cash stood at $493.0 million on Sept. 30. The stock closed Friday 27.92% above Thursday's close, and the gap began in after-hours trading right after the release.

The gap opened after hours and widened in the regular session

Thursday's regular session closed at $68.98, down 5.19% after an 8.04% gain on Wednesday. That Wednesday rise came before the report, so it was not a reaction to it. After the release, shares rose 11.63% in after-hours trading, to $77.00.

In pre-market trading (before the regular session) on Friday, Nov. 6, shares reached $81.25. That was 5.52% above the after-hours close and 17.79% above Thursday's close, on thin volume of 26,297 shares.

The regular session ranged from $76.50 to $88.44 and closed at $88.24, up 8.6% from the pre-market close. Volume was 2,694,294 shares, 3.21 times the 10-day average pace and 8.1% of the 33.41 million-share float (the shares available to trade). In after-hours trading Friday, shares were at $87.79, 0.51% below the close, on 1,031,000 shares.

Before the report, the stock had fallen 12.68% across the Oct. 8 to Nov. 5 sessions, with a low of $64.64 on Oct. 30.

Results topped analyst estimates, and two firms raised targets

Analysts had expected adjusted earnings of $0.29 per share and revenue of $177.584 million. The company reported $0.51 and $203.0 million.

Canaccord Genuity kept its Buy rating and raised its price target to $120 on Friday. Needham also kept its Buy rating and raised its target to $110.

Operating expenses jumped while net income fell

  • Growth: Product revenue was $113.4 million, up 29%. Service revenue was $89.6 million, up 60%, or 43% on an organic basis (growth without acquisitions). Total organic growth was 35%. The company credited higher liver and heart volume in its National OCS Program, logistics services and PAD Aviation, in which it invested on July 1. Chief Executive Waleed Hassanein said the quarter had record revenue and record case volume.
  • Margins: Gross margin was 58.5%, against 58.8% a year earlier. The company said a higher share of service revenue pulled it down, partly offset by lower scrap and logistics efficiencies.
  • Spending: Operating expenses included planned investment in OCS Kidney, next-generation OCS and ENHANCE clinical programs, added headcount, and infrastructure including the U.S. headquarters and PAD Aviation. Stock compensation was $12.1 million, up from $8.7 million.
  • Profit: Operating income was $28.1 million, against $23.3 million. Net income was $17.1 million, or $0.46 per diluted share, against $24.3 million, or $0.66. Adjusted net income was $18.9 million, against $24.5 million.

The company also named Fernando Araujo, a former chief financial officer of a GE HealthCare imaging segment, as its CFO in September.

Trials and European launches the company has outlined

  • The U.S. Food and Drug Administration approved investigational device exemptions for the ENHANCE Heart Part B and DENOVO Lung trials in October. Both will use the company's CHOPS preservation system as a control arm.
  • Enrollment in ENHANCE Heart Part A is complete, and the FDA approved a continued access protocol for 90 more patients.
  • The company said it plans to launch its National OCS Program in Italy, the Netherlands and Belgium, after winning its first Italian logistics tender in October.
  • The company said OCS Kidney is expected to reach its first human use in clinical studies in the second half of 2027.

Bottom line

TransMedics grew revenue 41% and raised its forecast, while adjusted earnings per share fell to $0.51 from $0.67 as spending on trials, hiring and Europe climbed. Cash was $493.0 million at the end of September. Shares ended Friday near the top of the day's range.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report